ESM accompanying the original article “Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial” by Tonneijck L et al

ESM Fig. 4 Subgroup-analyses of GFR response to intravenous GLP-1RA exenatide administration in overweight patients with type 2 diabetes

Data are shown as mean (95% confidence interval)

*Calculated using the MDRD study equation: 186 × (serum creatinine [mg/dl])\(^{-1.154}\) × (age [year])\(^{-0.203}\) × (0.742, if female) [1]

References